Sep 18, 2017 Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer
Sep 11, 2017 Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress
Aug 1, 2017 Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
Jul 26, 2017 Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
Jun 29, 2017 Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.
